New HER-Vaxx Cancer Vaccine trial data presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer
SYDNEY, Australia, 8 July 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced new clinical data from the Phase Ib study of its HER-Vaxx cancer vaccine showing cancer fighting antibody and clinical response rates continue to be positive in the patients receiving the optimal biological dose of vaccine.
For further information please download the attached PDF:
Download this document
